Biodistribution and kinetic characters of radiopharmaceutical medication based on biospecific antibodies to tumor-associated stroma elements and 177lutcium
Authors:
- Alexander P. TrashkovATAlexander P. Trashkov
- Tamara D. GagloevaTGTamara D. Gagloeva
- Alexander I. BudkoABAlexander I. Budko
- Olyesya I. TimaevaOTOlyesya I. Timaeva
- Marina Yu. KopaevaMKMarina Yu. Kopaeva
- Anton B. CherepovACAnton B. Cherepov
- Nikolay V. TsyganNTNikolay V. Tsygan
- Andrei A. StanzhevskyASAndrei A. Stanzhevsky
- Andrey G. VasilievAndrey G. Vasiliev
- Mariya A. PahomovaMPMariya A. Pahomova
- Christina A. SergunovaCSChristina A. Sergunova
- 26 December 2022
- journal article
- research article
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 13 (5) , 51-60
Abstract
Biodistribution and kinetics were studied of potentially target biospecific radiopharmaceutical medication for the treatment of malignant tumors of various histologic type and location with expression of cytotoxic T-lymphocyte membrane associated glycoprotein 4 and glucocorticoid Induced Tumor Necrosis Factor Receptor) 177Lu-DOTA-anti-CTLA4-GITR. Colorectal cancer experimental model has been successfully reproduced by means of murine large intestine experimental adenocarcinoma cells (AKATOL) СТ26 EGFR) direct transplantation. The model was characteristic of moderate growth rate and practically complete absence of metastatic spread. Immunohistochemical assay of tumor tissue has revealed satisfactory expression level of target antigens for the medication under study, i.e. cytotoxic T-lymphocyte associated protein 4 (CTLA4) as well as membrane receptor of tumor necrosis factor group (GITR). This medication 177Lu-DOTA-anti-CTLA4-GITR has been shown to store in the tumor tissue. Its major pathways out of the organism were through urinary system. On the other hand, the medication has also been demonstrated to store in non-target tissues, namely: kidneys, liver, large intestine. The results of this study may be used in preclinical studies of medications and serve as a basis for broader studies of 177Lu-DOTA-anti-CTLA4-GITR and its safety.Keywords
This publication has 14 references indexed in Scilit:
- Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinomaJournal of Clinical Investigation, 2020
- Immunogenic chemotherapy in two mouse colon cancer modelsCancer Science, 2020
- Characterization of the tumor cell microenvironmentP.A. Herzen Journal of Oncology, 2018
- Molecular-genetic mechanisms of initiation, promotion and progression of tumorsRussian Journal of Biotherapy, 2017
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunityNature, 2017
- Tumour-associated antigens and their anti-cancer applicationsEuropean Journal of Cancer Care, 2016
- Biomarkers of aging, life span and spontaneous carcinogenesis in the wild type and HER-2 transgenic FVB/N female miceBiogerontology, 2015
- P388 Leukemia in CDF1 Mice as the Test System for Studies of Tumor-Associated Neoangiogenesis and HypercoagulationBulletin of Experimental Biology and Medicine, 2015
- Tumour-associated macrophages and cancerCurrent Opinion in Pharmacology, 2013
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast CancerJournal of Clinical Oncology, 2010